Enlivex Therapeutics Ltd. (TLV:ENLV)

Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
508.00
+58.60 (13.04%)
Jul 30, 2025, 4:36 PM IDT
13.04%
Market Cap113.19M
Revenue (ttm)n/a
Net Income (ttm)-53.34M
Shares Outn/a
EPS (ttm)-2.47
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume123,353
Average Volume24,289
Open456.90
Previous Close449.40
Day's Range456.90 - 510.00
52-Week Range309.30 - 628.90
Beta0.79
RSI64.61
Earnings DateAug 29, 2025

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2005
Country Israel
Stock Exchange Tel Aviv Stock Exchange
Ticker Symbol ENLV
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.